JP2024505948A - タンパク質ｍ類似体及び融合タンパク質、並びに抗体機能を阻害するためのそれらの使用 - Google Patents

タンパク質ｍ類似体及び融合タンパク質、並びに抗体機能を阻害するためのそれらの使用 Download PDF

Info

Publication number
JP2024505948A
JP2024505948A JP2023546323A JP2023546323A JP2024505948A JP 2024505948 A JP2024505948 A JP 2024505948A JP 2023546323 A JP2023546323 A JP 2023546323A JP 2023546323 A JP2023546323 A JP 2023546323A JP 2024505948 A JP2024505948 A JP 2024505948A
Authority
JP
Japan
Prior art keywords
protein
functional fragment
mycoplasma
subject
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505948A5 (https=
Inventor
チャールズ アスキュー
チェンウェン リー
ブライアン クールマン
デイビッド フォレスト シーカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2024505948A publication Critical patent/JP2024505948A/ja
Publication of JP2024505948A5 publication Critical patent/JP2024505948A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023546323A 2021-02-03 2022-02-03 タンパク質ｍ類似体及び融合タンパク質、並びに抗体機能を阻害するためのそれらの使用 Pending JP2024505948A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145188P 2021-02-03 2021-02-03
US63/145,188 2021-02-03
PCT/US2022/015127 WO2022169984A1 (en) 2021-02-03 2022-02-03 Protein m analogs and fusion proteins and their use for inhibiting antibody function

Publications (2)

Publication Number Publication Date
JP2024505948A true JP2024505948A (ja) 2024-02-08
JP2024505948A5 JP2024505948A5 (https=) 2025-02-10

Family

ID=82741771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546323A Pending JP2024505948A (ja) 2021-02-03 2022-02-03 タンパク質ｍ類似体及び融合タンパク質、並びに抗体機能を阻害するためのそれらの使用

Country Status (7)

Country Link
US (1) US20240309055A1 (https=)
EP (1) EP4288445A1 (https=)
JP (1) JP2024505948A (https=)
KR (1) KR20230152008A (https=)
CN (1) CN117203226A (https=)
AU (1) AU2022216272A1 (https=)
WO (1) WO2022169984A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018320849A1 (en) * 2017-08-25 2020-03-05 Ovid Therapeutics Inc. Recombinant adeno-associated vectors
CN112877297A (zh) * 2021-03-27 2021-06-01 哈尔滨元亨生物药业有限公司 一种利用生物反应器制备猫瘟热病毒单克隆抗体的方法
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US9593150B2 (en) * 2012-07-16 2017-03-14 The Scripps Research Institute Immunoglobulin-binding human mycoplasma antigens and methods of use thereof
WO2015117057A2 (en) * 2014-01-31 2015-08-06 The Scripps Research Institute Protein m related immunoglobulin-binding polypeptides
KR20220053575A (ko) * 2019-08-01 2022-04-29 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 항체 결합 및 중화 항체 억제를 위한 조성물 및 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASKEW, C.: "A Vector independent method of neutralizing antibody evasion potency protects AAV for efficient gene", MOLECULAR THERAPY, vol. Vol.28, No.4S1, JPN6025051474, 28 April 2020 (2020-04-28), pages 22, ISSN: 0005758795 *
SAWITRI KN. ET AL.: "Investigating the effect of mutation on the thermo stability of GB1 protein", JOURNAL OF PHYSICS: CONF. SERIES, vol. 1011, JPN6024032785, 2018, pages 012084, ISSN: 0005758796 *

Also Published As

Publication number Publication date
WO2022169984A1 (en) 2022-08-11
KR20230152008A (ko) 2023-11-02
CN117203226A (zh) 2023-12-08
AU2022216272A1 (en) 2023-08-17
AU2022216272A9 (en) 2024-05-02
US20240309055A1 (en) 2024-09-19
EP4288445A1 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
JP7390693B2 (ja) 抗体回避性ウイルスベクターのための方法および組成物
ES3040934T3 (en) Modified capsid proteins for enhanced delivery of parvovirus vectors
CN110770346B (zh) 多倍体腺相关病毒载体及其制备和使用方法
JP2026000908A (ja) 抗体に結合して中和抗体を阻害するための組成物および方法
JP2024505948A (ja) タンパク質ｍ類似体及び融合タンパク質、並びに抗体機能を阻害するためのそれらの使用
JP2023524577A (ja) 改変アデノ随伴ウイルス５カプシドおよびその使用
CN111876432B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
CN113767110A (zh) 用于双重聚糖结合aav2.5载体的方法和组合物
AU2021224551A1 (en) AAV capsid-promoter interactions and cell selective gene expression
JP2023510266A (ja) 合成アデノ随伴ウイルス逆位末端反復、およびプロモーターとしてのそれらの使用の方法
US20220347315A1 (en) Methods and compositions for increasing transduction efficiency with cell membrane fusion proteins
US20240271115A1 (en) Methods and compositions for depleting antibodies
JP2023547992A (ja) 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物
HK40104382A (zh) 多倍体腺相关病毒载体及其制备和使用方法
HK40060027A (zh) 用於双重聚糖结合aav2‧5载体的方法和组合物
HK1260937A1 (en) Modified capsid proteins for enhanced delivery of parvovirus vectors
HK40022719B (zh) 多倍体腺相关病毒载体及其制备和使用方法
HK1260937B (en) Modified capsid proteins for enhanced delivery of parvovirus vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260316